First-line eradication for Helicobacter pylori -positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype

Yoshimasa Saito, Hiroshi Serizawa, Yukako Kato, Masaru Nakano, Masahiko Nakamura, Hidetsugu Saito, Hidekazu Suzuki, Takanori Kanai

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

AIM: To evaluate the effect of first line esomeprazole (EPZ)-based triple therapy on Helicobacter pylori (H. Pylori) eradication. METHODS: A total of 80 Japanese patients with gastritis who were diagnosed as positive for H. Pylori infection by endoscopic biopsy-based or 13C-urea breath tests were included in this study. The average age of the patients was 57.2 years (male/female, 42/38). These patients were treated by first-line eradication therapy with EPZ 40 mg/d, amoxicillin 1500 mg/d, and clarithromycin 400 mg/d for 7 d. All drugs were given twice per day. Correlations between H. Pylori eradication, CYP2C19 genotype, and serum pepsinogen (PG) level were analyzed. This study was registered with the UMIN Clinical Trials Registry (UMIN000009642). RESULTS: The H. Pylori eradication rates by EPZbased triple therapy evaluated by intention-to-treat and per protocol were 67.5% and 68.4%, respectively, which were similar to triple therapies with other first-generation proton pump inhibitors (PPIs). The eradication rates in three different CYP2C19 genotypes, described as extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer, were 52.2%, 72.1%, and 84.6%, respectively. The H. Pylori eradication rate was significantly lower in EM than non-EM (P <0.05). The serum PG I level and PG I/II ratio were significantly increased after eradication of H. Pylori (P <0.01), suggesting that gastric atrophy was improved by H. Pylori eradication. Thus, first-line eradication by EPZbased triple therapy for patients with H. Pylori -positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with other firstgeneration PPIs in the Japanese population. CONCLUSION: The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. Pylori eradication compared to other firstgeneration PPIs.

Original languageEnglish
Pages (from-to)13548-13554
Number of pages7
JournalWorld Journal of Gastroenterology
Volume21
Issue number48
DOIs
Publication statusPublished - 2015 Dec 28

Fingerprint

Esomeprazole
Gastritis
Helicobacter pylori
Genotype
Pepsinogen A
Proton Pump Inhibitors
Therapeutics
Pepsinogen C
Cytochrome P-450 CYP2C19
Breath Tests
Clarithromycin
Amoxicillin
Helicobacter Infections
Serum
Atrophy
Registries
Urea
Stomach
Clinical Trials
Biopsy

Keywords

  • CYP2C19
  • Esomeprazole
  • Helicobacter pylori
  • Pepsinogen
  • Proton pump inhibitor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

First-line eradication for Helicobacter pylori -positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype. / Saito, Yoshimasa; Serizawa, Hiroshi; Kato, Yukako; Nakano, Masaru; Nakamura, Masahiko; Saito, Hidetsugu; Suzuki, Hidekazu; Kanai, Takanori.

In: World Journal of Gastroenterology, Vol. 21, No. 48, 28.12.2015, p. 13548-13554.

Research output: Contribution to journalArticle

@article{7d127c1c4a15477784b499dbc6c62243,
title = "First-line eradication for Helicobacter pylori -positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype",
abstract = "AIM: To evaluate the effect of first line esomeprazole (EPZ)-based triple therapy on Helicobacter pylori (H. Pylori) eradication. METHODS: A total of 80 Japanese patients with gastritis who were diagnosed as positive for H. Pylori infection by endoscopic biopsy-based or 13C-urea breath tests were included in this study. The average age of the patients was 57.2 years (male/female, 42/38). These patients were treated by first-line eradication therapy with EPZ 40 mg/d, amoxicillin 1500 mg/d, and clarithromycin 400 mg/d for 7 d. All drugs were given twice per day. Correlations between H. Pylori eradication, CYP2C19 genotype, and serum pepsinogen (PG) level were analyzed. This study was registered with the UMIN Clinical Trials Registry (UMIN000009642). RESULTS: The H. Pylori eradication rates by EPZbased triple therapy evaluated by intention-to-treat and per protocol were 67.5{\%} and 68.4{\%}, respectively, which were similar to triple therapies with other first-generation proton pump inhibitors (PPIs). The eradication rates in three different CYP2C19 genotypes, described as extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer, were 52.2{\%}, 72.1{\%}, and 84.6{\%}, respectively. The H. Pylori eradication rate was significantly lower in EM than non-EM (P <0.05). The serum PG I level and PG I/II ratio were significantly increased after eradication of H. Pylori (P <0.01), suggesting that gastric atrophy was improved by H. Pylori eradication. Thus, first-line eradication by EPZbased triple therapy for patients with H. Pylori -positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with other firstgeneration PPIs in the Japanese population. CONCLUSION: The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. Pylori eradication compared to other firstgeneration PPIs.",
keywords = "CYP2C19, Esomeprazole, Helicobacter pylori, Pepsinogen, Proton pump inhibitor",
author = "Yoshimasa Saito and Hiroshi Serizawa and Yukako Kato and Masaru Nakano and Masahiko Nakamura and Hidetsugu Saito and Hidekazu Suzuki and Takanori Kanai",
year = "2015",
month = "12",
day = "28",
doi = "10.3748/wjg.v21.i48.13548",
language = "English",
volume = "21",
pages = "13548--13554",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "48",

}

TY - JOUR

T1 - First-line eradication for Helicobacter pylori -positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype

AU - Saito, Yoshimasa

AU - Serizawa, Hiroshi

AU - Kato, Yukako

AU - Nakano, Masaru

AU - Nakamura, Masahiko

AU - Saito, Hidetsugu

AU - Suzuki, Hidekazu

AU - Kanai, Takanori

PY - 2015/12/28

Y1 - 2015/12/28

N2 - AIM: To evaluate the effect of first line esomeprazole (EPZ)-based triple therapy on Helicobacter pylori (H. Pylori) eradication. METHODS: A total of 80 Japanese patients with gastritis who were diagnosed as positive for H. Pylori infection by endoscopic biopsy-based or 13C-urea breath tests were included in this study. The average age of the patients was 57.2 years (male/female, 42/38). These patients were treated by first-line eradication therapy with EPZ 40 mg/d, amoxicillin 1500 mg/d, and clarithromycin 400 mg/d for 7 d. All drugs were given twice per day. Correlations between H. Pylori eradication, CYP2C19 genotype, and serum pepsinogen (PG) level were analyzed. This study was registered with the UMIN Clinical Trials Registry (UMIN000009642). RESULTS: The H. Pylori eradication rates by EPZbased triple therapy evaluated by intention-to-treat and per protocol were 67.5% and 68.4%, respectively, which were similar to triple therapies with other first-generation proton pump inhibitors (PPIs). The eradication rates in three different CYP2C19 genotypes, described as extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer, were 52.2%, 72.1%, and 84.6%, respectively. The H. Pylori eradication rate was significantly lower in EM than non-EM (P <0.05). The serum PG I level and PG I/II ratio were significantly increased after eradication of H. Pylori (P <0.01), suggesting that gastric atrophy was improved by H. Pylori eradication. Thus, first-line eradication by EPZbased triple therapy for patients with H. Pylori -positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with other firstgeneration PPIs in the Japanese population. CONCLUSION: The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. Pylori eradication compared to other firstgeneration PPIs.

AB - AIM: To evaluate the effect of first line esomeprazole (EPZ)-based triple therapy on Helicobacter pylori (H. Pylori) eradication. METHODS: A total of 80 Japanese patients with gastritis who were diagnosed as positive for H. Pylori infection by endoscopic biopsy-based or 13C-urea breath tests were included in this study. The average age of the patients was 57.2 years (male/female, 42/38). These patients were treated by first-line eradication therapy with EPZ 40 mg/d, amoxicillin 1500 mg/d, and clarithromycin 400 mg/d for 7 d. All drugs were given twice per day. Correlations between H. Pylori eradication, CYP2C19 genotype, and serum pepsinogen (PG) level were analyzed. This study was registered with the UMIN Clinical Trials Registry (UMIN000009642). RESULTS: The H. Pylori eradication rates by EPZbased triple therapy evaluated by intention-to-treat and per protocol were 67.5% and 68.4%, respectively, which were similar to triple therapies with other first-generation proton pump inhibitors (PPIs). The eradication rates in three different CYP2C19 genotypes, described as extensive metabolizer (EM), intermediate metabolizer, and poor metabolizer, were 52.2%, 72.1%, and 84.6%, respectively. The H. Pylori eradication rate was significantly lower in EM than non-EM (P <0.05). The serum PG I level and PG I/II ratio were significantly increased after eradication of H. Pylori (P <0.01), suggesting that gastric atrophy was improved by H. Pylori eradication. Thus, first-line eradication by EPZbased triple therapy for patients with H. Pylori -positive gastritis was influenced by CYP2C19 genotype, and the eradication rate was on the same level with other firstgeneration PPIs in the Japanese population. CONCLUSION: The results from this study suggest that there is no advantage to EPZ-based triple therapy on H. Pylori eradication compared to other firstgeneration PPIs.

KW - CYP2C19

KW - Esomeprazole

KW - Helicobacter pylori

KW - Pepsinogen

KW - Proton pump inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84953223959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84953223959&partnerID=8YFLogxK

U2 - 10.3748/wjg.v21.i48.13548

DO - 10.3748/wjg.v21.i48.13548

M3 - Article

C2 - 26730167

AN - SCOPUS:84953223959

VL - 21

SP - 13548

EP - 13554

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 48

ER -